Elromo 25 mg / 50 mg Tablets (Eltrombopag) – Product Information

Elromo 25 mg and 50 mg Tablets, containing Eltrombopag, are prescription medicines used under specialist supervision to manage certain conditions associated with low platelet counts. Cordium Pharmaceuticals Pvt Ltd provides product information and pharmaceutical supply enquiry support for eligible international buyers, subject to destination-country regulations and product availability.

Product Description: Elromo Tablets

Elromo contains Eltrombopag, a thrombopoietin receptor agonist that stimulates platelet production in the bone marrow. It may be prescribed for specific blood disorders, including persistent or chronic immune thrombocytopenia (ITP), when previous treatments have not provided an adequate response. Eltrombopag is also used for certain patients with severe aplastic anaemia and, in specific circumstances, thrombocytopenia associated with chronic hepatitis C treatment. Approved uses vary by product label and country.

Elromo is available in the 25 mg and 50 mg tablet strengths. The appropriate strength depends on the patient's diagnosis, age, liver function, platelet count and response to treatment. Always verify the product's approved indications and prescribing information before use.

Benefits and Uses of Eltrombopag

Eltrombopag supports platelet production and may help increase platelet counts in eligible patients. Its potential clinical benefits include:

Immune thrombocytopenia (ITP): Helps manage low platelet counts in patients who have not responded adequately to certain previous treatments.

Severe aplastic anaemia: May be used as part of specialist-directed treatment for selected patients.

Selected hepatitis C treatment settings: May help address thrombocytopenia where permitted by the applicable treatment guidelines and product label.

Platelet count management: Helps clinicians manage platelet levels and assess treatment response through regular blood tests.

Treatment goals and outcomes vary between patients. Eltrombopag does not cure every underlying condition, and an increase in platelet count does not eliminate all bleeding risks.

Side Effects and Safety Information

Eltrombopag may cause side effects. Commonly reported effects include nausea, diarrhoea, headache, tiredness, fever, cough and changes in liver function test results.

Important safety risks include liver injury and blood clots, which may be serious. Some patients may also experience cataracts or changes in bone marrow test results. Seek urgent medical attention for symptoms such as unusual bleeding, severe abdominal pain, yellowing of the skin or eyes, chest pain, breathing difficulty or sudden weakness.

Doctors may monitor platelet counts, liver function and other relevant laboratory results before and during treatment. Patients should tell their healthcare professional about existing liver problems, previous blood clots, pregnancy, breastfeeding and all medicines or supplements they use.

Do not start, stop or change the dose without medical advice.

Frequently Asked Questions (FAQs)

1. What is Elromo 25 mg / 50 mg used for?

Elromo contains Eltrombopag, which may be prescribed for certain conditions involving low platelet counts, including immune thrombocytopenia and selected cases of severe aplastic anaemia.

2. How does Eltrombopag work?

Eltrombopag activates the thrombopoietin receptor, stimulating processes in the bone marrow that support platelet production.

3. What is the difference between Elromo 25 mg and 50 mg?

The tablets contain different strengths of the same active ingredient. A healthcare professional determines the appropriate dose according to the patient's condition, test results and treatment response.

4. Can Elromo be taken without a prescription?

No. Eltrombopag requires medical supervision because it can cause serious adverse effects and requires laboratory monitoring.

5. How can international buyers enquire about Elromo?

Hospitals, pharmaceutical distributors and other eligible importers may contact Cordium Pharmaceuticals Pvt Ltd to enquire about product availability, quotations, packaging documentation and export requirements. Supply is subject to applicable laws and regulatory approvals in the destination market.

Enquire About Elromo Tablets

Cordium Pharmaceuticals Pvt Ltd supports pharmaceutical product enquiries for eligible international buyers. Contact the company for current availability, applicable product documentation, quotation details and export arrangements, subject to local import regulations.

Medical disclaimer: This content is for general informational purposes only and is not a substitute for professional medical advice or the approved product leaflet.